Baricitinib versus placebo or adalimumab in rheumatoid arthritis
<h4>Background</h4> <p>Baricitinib is an oral, reversible, JAK1/JAK2 inhibitor that may have therapeutic value in patients with rheumatoid arthritis.</p> <h4>Methods</h4> <p>In this 52-week, phase 3, double-blind, placebo and active-controlled study, 1307 p...
Príomhchruthaitheoirí: | Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y |
---|---|
Formáid: | Journal article |
Foilsithe / Cruthaithe: |
Massachusetts Medical Society
2017
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’une étude de phase 3 de 52 semaines RA-BEAM
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2016) -
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
de réir: Keystone, E, et al.
Foilsithe / Cruthaithe: (2017) -
Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2017) -
Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
de réir: Emery, P, et al.
Foilsithe / Cruthaithe: (2017) -
Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
de réir: Taylor, P, et al.
Foilsithe / Cruthaithe: (2016)